- Home
- SLN vs LEO Comparison
SLN vs LEO Comparison
Compare SLN & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- LEO
- Stock Information
- Founded
- SLN 1994
- LEO 1987
- Country
- SLN United Kingdom
- LEO United States
- Employees
- SLN N/A
- LEO N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- LEO Trusts Except Educational Religious and Charitable
- Sector
- SLN Health Care
- LEO Finance
- Exchange
- SLN Nasdaq
- LEO Nasdaq
- Market Cap
- SLN 352.2M
- LEO 394.9M
- IPO Year
- SLN N/A
- LEO N/A
- Fundamental
- Price
- SLN $6.47
- LEO $6.18
- Analyst Decision
- SLN Strong Buy
- LEO
- Analyst Count
- SLN 4
- LEO 0
- Target Price
- SLN $61.50
- LEO N/A
- AVG Volume (30 Days)
- SLN 959.2K
- LEO 200.2K
- Earning Date
- SLN 11-14-2024
- LEO 01-01-0001
- Dividend Yield
- SLN N/A
- LEO 4.01%
- EPS Growth
- SLN N/A
- LEO N/A
- EPS
- SLN N/A
- LEO 0.04
- Revenue
- SLN $21,773,221.00
- LEO N/A
- Revenue This Year
- SLN N/A
- LEO N/A
- Revenue Next Year
- SLN $104.98
- LEO N/A
- P/E Ratio
- SLN N/A
- LEO $152.00
- Revenue Growth
- SLN N/A
- LEO N/A
- 52 Week Low
- SLN $5.81
- LEO $4.98
- 52 Week High
- SLN $27.72
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- SLN 27.24
- LEO 34.47
- Support Level
- SLN $6.06
- LEO $6.34
- Resistance Level
- SLN $8.88
- LEO $6.47
- Average True Range (ATR)
- SLN 0.72
- LEO 0.06
- MACD
- SLN 0.22
- LEO -0.02
- Stochastic Oscillator
- SLN 22.52
- LEO 7.26
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others.